moneyheap
KYMR · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Kymera Therapeutics, Inc. Common Stock (KYMR) stock moving?
KYMR closed at $136.64 on Nov 10, about 23% above the $110.76 close on Oct 23, and traded near its $142.92 intraday high that day. The rally followed the Oct 29 third-quarter release, which reported positive healthy-volunteer Phase 1 data for the oral IRF5 degrader KT-579 showing deep, sustained degradation and a favorable safety profile. Volume rose from roughly 0.4-0.8M shares a day before the release to 1.3-1.8M on Oct 30 to Nov 4, and has stayed near 1.0-1.3M on Nov 9-10, which supports the move. The quarter was not clean: Q3 EPS of $(1.32) missed the $(1.27) estimate. The balance sheet is strong, with $1.6B in cash and runway into 2029. Analysts responded with higher targets: Barclays reaffirmed Overweight with a $170 target (from $139), Truist kept Buy at $150, and RBC kept Sector Perform at $116, which sits below the current price. The main near-term catalyst is the KT-621 BROADEN2 Phase 2b atopic dermatitis topline, due by year-end 2026, with a KT-579 lupus Phase 1b start planned by early 2027 and the BREADTH asthma readout in late 2027. The stock pulled back to $128.12 on Nov 5 after a $136.25 close on Nov 4, then recovered, so buyers have been active on dips. Key risks are the binary readout, the wide Q3 loss, and the divergence between the most bullish and most cautious analyst targets.
News behind the analysis
- Barclays Maintains Overweight Rating and Raises Price Target for Kymera TherapeuticsBarclays reaffirmed its Overweight rating and raised its price target from $139 to $170.
- Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170Benzinga reported the same Barclays action, with the price target raised to $170.
- Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150Truist kept its Buy rating and raised its price target to $150 after the third-quarter update.
- RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116RBC kept its Sector Perform rating and raised its price target to $116, still below the latest close.
- Analysts Adjust Price Targets for Kymera TherapeuticsTruist, BTIG and RBC adjusted their price targets following the company's recent updates.
- Kymera Therapeutics Reports Third Quarter 2026 Financial Results and Positive KT-579 Phase 1 DataQ3 results came with positive KT-579 Phase 1 healthy-volunteer data, $1.6B in cash and runway into 2029. The KT-621 BROADEN2 Phase 2b topline is due by year-end 2026.
- Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) EstimateThe third-quarter loss per share of $1.32 was wider than the $1.27 consensus estimate.
- Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial ResultsThe company scheduled the KT-579 Phase 1 results for release on Oct 29 with its Q3 financials.
- Kymera Therapeutics To Announce Results From Its Phase 1 Clinical Trial Evaluating Single And Multiple-Ascending Doses Of KT-579 In Healthy Volunteers On October 29Benzinga reported the scheduled release of KT-579 single and multiple ascending dose Phase 1 results on Oct 29.
About Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics is a clinical-stage biotech in Watertown, Massachusetts, developing oral small-molecule drugs for immune and inflammatory diseases. Its drugs are protein degraders: instead of blocking a disease-causing protein, they make the cell break it down. Its lead programs are KT-621 (a STAT6 degrader) and KT-579, which is headed into an early-stage lupus trial.
How it makes money
Kymera has no approved products, so it earns no sales revenue. Its income is irregular collaboration revenue from partners. In 2026 that included a $45M option fee from Gilead and a $20M Sanofi milestone for KT-485. The company expects no more collaboration revenue in 2026. It funds its losses mainly from cash raised from investors, about $1.6B as of late 2026, which it says will last into 2029.
What usually moves KYMR
- Clinical trial results for KT-621 and KT-579
- Partnership milestones and deals (Sanofi, Gilead)
- Regulatory news such as FDA designations
- Investor sentiment toward the biotech sector and interest rates
- Competing immunology drugs and other protein-degrader companies
Similar companies
ARVN, NRIX, FHTX, C4T, APGE